Holen Sie sich die Stockscreener-App
0.1015
497.06%
0.0845
Schlusskurs vom Vortag:
$0.017
Offen:
$0.1015
24-Stunden-Volumen:
2,621
Relative Volume:
1.28
Marktkapitalisierung:
$N/A
Einnahmen:
-
Nettoeinkommen (Verlust:
$149.05M
KGV:
0.0511
EPS:
1.9846
Netto-Cashflow:
$-6.05M
1W Leistung:
+497.06%
1M Leistung:
+497.06%
6M Leistung:
+497.06%
1J Leistung:
-96.95%
1-Tages-Spanne:
$0.1015
$0.1015
1-Wochen-Bereich:
$0.1015
$0.1015
52-Wochen-Spanne:
$0.017
$0.1015
Galera Therapeutics Inc Stock (GRTX) Company Profile
Firmenname
Galera Therapeutics Inc
Sektor
Branche
Telefon
-
Adresse
-
Compare GRTX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GRTX
Galera Therapeutics Inc
|
0.1015 | 0 | 0 | 149.05M | -6.05M | 1.9846 |
VRTX
Vertex Pharmaceuticals Inc
|
425.31 | 109.41B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
705.83 | 76.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
783.89 | 48.20B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
302.73 | 40.31B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
293.60 | 33.13B | 5.36B | 287.73M | 924.18M | 2.5229 |
Galera Therapeutics Inc Stock (GRTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-08-10 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-10-19 | Herabstufung | BTIG Research | Buy → Neutral |
| 2021-10-19 | Herabstufung | BofA Securities | Buy → Underperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-12-16 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2020-12-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-12-02 | Eingeleitet | BTIG Research | Buy |
| 2019-12-02 | Eingeleitet | BofA/Merrill | Buy |
| 2019-12-02 | Eingeleitet | Citigroup | Buy |
| 2019-12-02 | Eingeleitet | Credit Suisse | Neutral |
Alle ansehen
Galera Therapeutics Inc Aktie (GRTX) Neueste Nachrichten
Malvern-based Galera Therapeutics to be acquired in reverse merger - MSN
Emerald backs Galera–Obsidian deal with 26.5% Galera (GRTX) stake - Stock Titan
Galera, Obsidian Agree to Merge, Raise $350 Million in Financing - MyChesCo
Obsidian CEO Madan Jagasia Leads Merger with Galera Therapeutics Backed by $350M Financing - INDIA New England News
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger-LEG, AVNS, GRTX, and GSAT - The Malaysian Reserve
Halper Sadeh LLC is Investigating Whether LEG, AVNS, SEM, GRTX are Obtaining Fair Deals for their Shareholders - GlobeNewswire Inc.
Merger Deal: Galera Therapeutics (GRTX) to Merge with Obsidian; ASCO Phase 2 Data Ahead - Stock Titan
Galera Therapeutics (NASDAQ: GRTX) to merge with Obsidian; S-4 and proxy planned - Stock Titan
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--LEG, AVNS, GRTX, and GSAT - Sahm
Galera, Obsidian to Merge, Raise $350 Million in Financing - MyChesCo
Are FORA, GRTX, WBS, TALK Obtaining Fair Deals for their Shareholders? - The Malaysian Reserve
[DEF 14A] Galera Therapeutics, Inc. Definitive Proxy Statement - Stock Titan
United StatesGoodwin Advises Obsidian Therapeutics On Merger With Galera Therapeutics And $350 Million Private Placement Financing - Mondaq
Galera Therapeutics to merge with Obsidian in $350M deal By Investing.com - Investing.com Australia
Obsidian and Galera reveal reverse merger plan - The Pharma Letter
Obsidian, Galera to advance cell therapy following reverse merger - BioPharma Dive
Galera (GRTX) to Merge with Obsidian; $350M Financing Backs OBX‑115 - Stock Titan
M&A Class Action Firm Investigating Galera Acquisition - National Today
Galera and Obsidian Announce $350M Merger, Advancing Novel TIL Therapies - National Today
Merger: Galera to combine with Obsidian (NASDAQ: GRTX) with $350M PIPE commitment - Stock Titan
Obsidian Therapeutics (NASDAQ: OBX) to list after merger with Galera, $350M PIPE - Stock Titan
Galera Therapeutics (GRTX) to file Form S-4 for proposed Obsidian merger - Stock Titan
Galera Therapeutics (GRTX) to Merge with Obsidian Therapeutics - GuruFocus
Obsidian Therapeutics, Inc. agreed to acquire Galera Therapeutics, Inc. in a reverse merger transaction. - marketscreener.com
Galera Therapeutics to merge with Obsidian in $350M deal - Investing.com
Galera Therapeutics, Obsidian Therapeutics Announce Merger and $350M Private Placement - citybiz
GRTX | GALERA THERAPEUTICS INC Insider Trading - Quiver Quantitative
GRTX Stock Alert: Halper Sadeh LLC is Investigating Whether Galera Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders - Bluefield Daily Telegraph
Galera Therapeutics and Obsidian Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement - ChartMill
Cell therapy biotech Obsidian leverages Galera reverse merger to go public - Fierce Biotech
Galera Therapeutics, Obsidian Therapeutics enter merger agreement - TipRanks
Galera Announces Obsidian Merger and $350M Financing - TipRanks
Galera Therapeutics (GRTX) to combine with Obsidian after $350M PIPE financing - Stock Titan
Galera Therapeutics to Merge With Obsidian; Secures $350 Million PIPE and Sets CVR for Legacy Assets - TradingView
Obsidian–Galera (OTC: GRTX) merger adds $350M PIPE to fund OBX-115 - Stock Titan
Obsidian Therapeutics and Galera Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement - Weekly Voice
GALERA THERAPEUTICS INCCO AND OBSIDIAN TO MERGE IN ALL-STOCK DEAL - Moomoo
[PRE 14A] Galera Therapeutics, Inc. Preliminary Proxy Statement - Stock Titan
Nancy T. Chang Discloses Investment at Galera Therapeutics with 5.9% Stake - TradingView
Director grows Galera (NASDAQ: GRTX) stake via private placement and merger - Stock Titan
Galera Therapeutics, Inc. Files Form 8-K: Company Information, Stock Symbol GRTX, and No Exchange Listing as of April 2026 - Minichart
Galera Therapeutics Announces Share Conversions and Warrant Exercise - TipRanks
Galera Therapeutics (GRTX) director IRA converts 5.34M preferred-linked shares - Stock Titan
[Form 4] Galera Therapeutics, Inc. Insider Trading Activity - Stock Titan
Preferred conversion and warrant exercise reshape Galera (GRTX) common stock - Stock Titan
Neogen® Corporation Announces Appointment of Jennifer Evans Stacey as Chief Legal & Compliance Officer and Board Secretary - Business Wire
Galera Sets Deadlines for 2026 Combined Annual Meeting - The Globe and Mail
Galera Therapeutics schedules combined 2025 and 2026 annual meeting for May - Investing.com Australia
Galera Therapeutics schedules combined 2025-2026 annual meeting for May 8, 2026; April 13 proposal deadline - TradingView
Galera Therapeutics (GRTX) sets 2026 meeting date and April 13 proposal deadline - Stock Titan
Galera Therapeutics 10-K: Revenue $0, EPS $0.64 on $149.0M Net Income - TradingView
Finanzdaten der Galera Therapeutics Inc-Aktie (GRTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.00%
0.53%
Kapitalisierung:
|
Volumen (24h):